Glimpse Of New Phase III Data Hints Pfizer's Eagerly-Awaited Oral RA Drug Is Still On Track
This article was originally published in The Pink Sheet Daily
JAK inhibitor tofacitinib, formerly called tasocitinib, meets primary endpoints in second Phase III study, could be filed in second half of 2011.
You may also be interested in...
JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases
Orally available, flexible and novel, Janus kinase inhibitors are poised to trigger major treatment shakeups in at least two disease spaces. Two drugs at the head of the JAK pack are close to coming of age – Pfizer Inc.’s tofacitinib and Incyte Corp.’s ‘18424 – and hopes are high, though questions remain about selectivity, long-term side effects and just how far the class can go.
Pfizer retains its lead in race to bring a novel oral RA drug to market
Pfizer’s latest major pipeline clear-out resulted in losses of Sutent development in a number of cancers and figitumumab in non-small cell lung cancer, among many other discontinuations.